| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $159K | +153.2% | +3.5% |
| SG&A Expense | $1.8M | +34.6% | +237.7% |
| Operating Income | -$1.9M | -40.0% | -184.3% |
| Net Income | -$1.9M | -53.5% | -185.7% |
| EPS (Basic) | -$0.07 | -40.0% | -133.3% |
| EPS (Diluted) | -$0.07 | -40.0% | -133.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $514K | — | +3.1% |
| Current Assets | $3.3M | — | — |
| Total Assets | $4.3M | — | — |
| Current Liabilities | $2.3M | — | — |
| Total Liabilities | $3.8M | — | — |
| Stockholders' Equity | $504K |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$1.4M | — | — |
| Investing Cash Flow | -$122K | — | — |
| Financing Cash Flow | $3.7M | — | — |
| +221.7% |